Monday , October 23 2017
Home / Letter From The Editor (page 90)

Letter From The Editor

Letter from the Editor #491

Have you ever experienced the “Diabetes Déjà Vu Factor”? Last week it was in Santa Monica, this week in Boston, both times limo drivers, both times diabetes, both times they did not know what to do. I got into the limo in Boston to run some errands and the conversation turned ...

Read More »

Letter from the Editor #490

This past weekend I was in California to serve on a panel discussing insulin protocols in both the hospital and long term care settings. There was a lot of great information on what different hospitals did. It was interesting to hear how the choice of pens or vials was made ...

Read More »

Letter from the Editor #489

This week, Steve and I have put together a great summary of the top stories from the European Association for the Study of Diabetes Conference in Salzburg, Austria. Although there was a lot of great news, the bottom line was not much new has occurred since the ADA Scientific Sessions ...

Read More »

Letter from the Editor #488

This week, the word “pancreatitis” is back in the news, as the FDA suspects that Merck & Co., Inc.’s blockbuster diabetes drug Januvia may be linked to serious cases of pancreatitis. Although many leading endocrinologists including Steve Edelman and Ralph DeFronzo have previously told us that patients with diabetes are ...

Read More »

Letter from the Editor #487

Video

All week long we’ve heard politicians, lobbyists and radio personalities weigh in with their opinions on a national health care system. It seems like the public option idea is what is driving the most discussions and debate. It also seems to me that maybe they should ask the people who ...

Read More »

Letter from the Editor #486

alt

This week Par Pharmaceutical announced that they had been granted approval to market generic Starlix (Nateglinide). See this week’s New Product. Does the approval of this generic effectively mean we have a new treatment for Diabetes available? I think it does. When Starlix and Prandin first came out, the state ...

Read More »

Letter from the Editor #485

There are two things that we have spent time bringing you information on over the past few weeks that won’t seem to go away.   The GDH-PQQ monitoring controversy has moved to the hospital setting as companies using different enzymes see a way to get their product on formulary. At ...

Read More »

Letter from the Editor #484

Another reason to monitor glucose: Better restaurant service Over the past few weeks I have started increasing my race walking mileage to prepare for a half marathon in November. Although I don’t have diabetes this increase in physical activities seems to run my glucose low in the morning. While driving ...

Read More »